ValuEngine Lowers Aquinox Pharmaceuticals, Inc. (AQXP) to Sell
Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) was downgraded by research analysts at ValuEngine from a “hold” rating to a “sell” rating in a research note issued on Friday.
A number of other equities research analysts also recently commented on AQXP. Zacks Investment Research raised Aquinox Pharmaceuticals from a “hold” rating to a “buy” rating and set a $15.00 price objective for the company in a research report on Thursday, August 10th. Canaccord Genuity set a $22.00 price objective on Aquinox Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, August 8th. Finally, BidaskClub raised Aquinox Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, August 4th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $22.25.
Aquinox Pharmaceuticals (NASDAQ:AQXP) traded down 9.19% during trading on Friday, hitting $12.85. The stock had a trading volume of 230,748 shares. Aquinox Pharmaceuticals has a one year low of $9.83 and a one year high of $19.97. The firm’s market cap is $301.51 million. The stock’s 50-day moving average is $14.28 and its 200 day moving average is $14.77.
Aquinox Pharmaceuticals (NASDAQ:AQXP) last announced its quarterly earnings data on Tuesday, August 8th. The company reported ($0.59) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.59). Equities analysts anticipate that Aquinox Pharmaceuticals will post ($2.15) earnings per share for the current year.
A number of hedge funds have recently bought and sold shares of AQXP. Nexthera Capital LP purchased a new stake in Aquinox Pharmaceuticals during the second quarter valued at about $1,276,000. Sphera Funds Management LTD. purchased a new stake in Aquinox Pharmaceuticals during the second quarter valued at about $874,000. Vanguard Group Inc. grew its position in Aquinox Pharmaceuticals by 6.6% during the second quarter. Vanguard Group Inc. now owns 282,483 shares of the company’s stock valued at $3,974,000 after acquiring an additional 17,455 shares during the period. Geode Capital Management LLC grew its position in Aquinox Pharmaceuticals by 10.0% during the first quarter. Geode Capital Management LLC now owns 121,532 shares of the company’s stock valued at $2,028,000 after acquiring an additional 11,035 shares during the period. Finally, Investment Centers of America Inc. purchased a new stake in Aquinox Pharmaceuticals during the first quarter valued at about $172,000. 95.15% of the stock is owned by hedge funds and other institutional investors.
About Aquinox Pharmaceuticals
Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Aquinox Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.